PFE

SEC source: 0001225208-26-003710 · doc4.xml · derivative · entry 1

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 759,400

Underlying: Common Stock · 1,630 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-26-003318 · doc4.xml · nonDerivative · entry 3

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,934

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

SEC source: 0001225208-26-003308 · doc4.xml · derivative · entry 1

de Germay Alexandre · CIK 0002005574 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 194,883

Underlying: Common Stock · 194,883 shares

Expires 2031-03-03

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-26-003309 · doc4.xml · derivative · entry 1

SAHNI PAYAL · CIK 0001817124 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,268

Underlying: Common Stock · 108,268 shares

Expires 2031-03-03

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-26-003310 · doc4.xml · derivative · entry 1

McDermott Michael · CIK 0001902464 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 151,576

Underlying: Common Stock · 151,576 shares

Expires 2031-03-03

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-26-003311 · doc4.xml · derivative · entry 1

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,284

Underlying: Common Stock · 82,284 shares

Expires 2031-03-03

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-26-003312 · doc4.xml · derivative · entry 1

Baum Andrew · CIK 0002029853 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 303,151

Underlying: Common Stock · 303,151 shares

Expires 2031-03-03

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-26-003313 · doc4.xml · derivative · entry 1

MALIK AAMIR · CIK 0001881510 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 194,883

Underlying: Common Stock · 194,883 shares

Expires 2031-03-03

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-26-003314 · doc4.xml · derivative · entry 1

LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 194,883

Underlying: Common Stock · 194,883 shares

Expires 2031-03-03

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-26-003315 · doc4.xml · derivative · entry 1

Denton David M · CIK 0001428718 · Chief Financial Officer & EVP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 216,537

Underlying: Common Stock · 216,537 shares

Expires 2031-03-03

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-26-003316 · doc4.xml · derivative · entry 1

BOSHOFF CHRISTOFFEL · CIK 0001988687 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 259,844

Underlying: Common Stock · 259,844 shares

Expires 2031-03-03

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-26-003318 · doc4.xml · derivative · entry 4

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,638

Underlying: Common Stock · 22,638 shares

Expires 2031-03-03

F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-26-003318 · doc4.xml · nonDerivative · entry 2

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,760

F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements.

SEC source: 0001225208-26-003318 · doc4.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,352

F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements.

SEC source: 0001225208-26-003317 · doc4.xml · derivative · entry 1

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 708,666

Underlying: Common Stock · 708,666 shares

Expires 2031-03-03

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-26-002921 · doc4.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,041

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

SEC source: 0001225208-26-002816 · doc4.xml · nonDerivative · entry 4

McDermott Michael · CIK 0001902464 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,308

F5 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

SEC source: 0001225208-26-002815 · doc4.xml · nonDerivative · entry 2

BOSHOFF CHRISTOFFEL · CIK 0001988687 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,379

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of performance share awards (including dividend equivalents thereon).

SEC source: 0001225208-26-002815 · doc4.xml · nonDerivative · entry 1

BOSHOFF CHRISTOFFEL · CIK 0001988687 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,212

F1 · shares: The reported transaction constitutes the earn-out of performance share awards (including dividend equivalents thereon).

SEC source: 0001225208-26-002816 · doc4.xml · derivative · entry 5

McDermott Michael · CIK 0001902464 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 37,925 shares

Expires 2026-02-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-26-002816 · doc4.xml · nonDerivative · entry 3

McDermott Michael · CIK 0001902464 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,811

F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-26-002816 · doc4.xml · nonDerivative · entry 2

McDermott Michael · CIK 0001902464 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,855

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

SEC source: 0001225208-26-002816 · doc4.xml · nonDerivative · entry 1

McDermott Michael · CIK 0001902464 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,534

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-26-002817 · doc4.xml · derivative · entry 4

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 56,888 shares

Expires 2026-02-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-26-002817 · doc4.xml · nonDerivative · entry 3

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,455

F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-26-002817 · doc4.xml · nonDerivative · entry 2

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,521

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

SEC source: 0001225208-26-002817 · doc4.xml · nonDerivative · entry 1

Fonseca Lidia · CIK 0001454944 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,579

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-26-002818 · doc4.xml · derivative · entry 5

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 491,626 shares

Expires 2026-02-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-26-002818 · doc4.xml · nonDerivative · entry 3

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 388,671

F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-26-002818 · doc4.xml · nonDerivative · entry 2

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 855,912

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

SEC source: 0001225208-26-002818 · doc4.xml · nonDerivative · entry 1

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 864,215

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-26-002819 · doc4.xml · derivative · entry 4

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,558 shares

Expires 2026-02-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-26-002819 · doc4.xml · nonDerivative · entry 3

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,696

F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-26-002819 · doc4.xml · nonDerivative · entry 2

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,383

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

SEC source: 0001225208-26-002819 · doc4.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,744

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-26-002820 · doc4.xml · derivative · entry 5

LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 122,907 shares

Expires 2026-02-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-26-002820 · doc4.xml · nonDerivative · entry 3

LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,177

F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-26-002820 · doc4.xml · nonDerivative · entry 2

LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 279,988

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

SEC source: 0001225208-26-002820 · doc4.xml · nonDerivative · entry 1

LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 282,186

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-26-002821 · doc4.xml · derivative · entry 5

SAHNI PAYAL · CIK 0001817124 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 56,888 shares

Expires 2026-02-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-26-002821 · doc4.xml · nonDerivative · entry 3

SAHNI PAYAL · CIK 0001817124 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,667

F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-26-002821 · doc4.xml · nonDerivative · entry 2

SAHNI PAYAL · CIK 0001817124 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,733

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

SEC source: 0001225208-26-002821 · doc4.xml · nonDerivative · entry 1

SAHNI PAYAL · CIK 0001817124 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,816

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-26-002481 · doc4.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,186

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

SEC source: 0001225208-26-002482 · doc4.xml · nonDerivative · entry 1

BOSHOFF CHRISTOFFEL · CIK 0001988687 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,829

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

SEC source: 0001225208-26-001988 · doc4.xml · derivative · entry 1

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 757,286

Underlying: Common Stock · 2,883 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-26-001126 · doc4.xml · nonDerivative · entry 1

BOSHOFF CHRISTOFFEL · CIK 0001988687 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,645

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

SEC source: 0001225208-26-000647 · doc4.xml · derivative · entry 1

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 743,136

Underlying: Common Stock · 79 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-26-000163 · doc4.xml · derivative · entry 1

BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 743,147

Underlying: Common Stock · 24 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-26-000188 · doc4.xml · derivative · entry 1

Taraporevala Cyrus · CIK 0001454920 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,349.741

Underlying: Common Stock · 1,506.024 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.